Neogen (NASDAQ:NEOG) Third Quarter 2025 Results

Key Financial Results

• Revenue: US$221.0m (down 3.4% from 3Q 2024).
• Net loss: US$11.0m (loss widened by 442% from 3Q 2024).
• US$0.05 loss per share (further deteriorated from US$0.009 loss in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Neogen Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 200%.

Looking ahead, revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.

The company's shares are down 31% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Neogen's balance sheet health.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.